A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variantsLinglei Jiang, Kenneth W. Witwer|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 25